Lonza appoints Wolfgang Wienand as new CEO

2 April 2024

Swiss contract development and manufacturing organization (CDMO) Lonza today announced that Wolfgang Wienand has been appointed chief executive (CEO), and will join the company during the summer of 2024.

Mr Wienand is currently CEO of the Swiss CDMO Siegfried Holding, a role he has held since 2019. Prior to this, he first served as chief scientific officer and then as chief strategy officer in Siegfried’s executive leadership team. Before joining Siegfried in 2010, Mr Wienand held a series of increasingly senior positions at the German specialty chemicals company Evonik Industries.

Mr Wienand will succeed Albert Baehny, charman, who took on the additional responsibility of CEO on an ad interim basis in October 2023 while the search for a permanent CEO took place. Mr Baehny will remain at Lonza for a transition period during the summer, before retiring from the company.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK